Table 14Risk of fracture for zoledronic acid, relative to placebo, by dose, frequency, and fracture group*

Author, yearStudy durationType of fractureRisk levelNumber of fractures, zoledronic acidNumber of fractures, placeboOdds ratio (95% CI)
5 MILLIGRAMS ONCE
Black, 2007139 36 monthsAny clinical; fractureHigh308/3667456/35630.63 (0.54, 0.72)
Black, 2007139 36 monthsNonvertebral fractureHigh292/3650388/36260.73 (0.62, 0.85)
Black, 2007139 36 monthsMorphometric vertebral fractureHigh92/2788310/28440.32 (0.26, 0.39)
Black, 2007139 36 monthsClinical vertebral fractureHigh19/380084/32310.23 (0.16, 0.34)
Black, 2007139 36 monthsHip fractureHigh52/371488/35200.56 (0.40, 0.78)
4 MILLIGRAMS ONCE
Reid, 2002138 12 monthsNonvertebral fractureIntermediate1/601/590.98 (0.06, 15.91)
Reid, 2002138 12 monthsVertebral fracturesIntermediate0/600/59NC
2 MILLIGRAMS, EVERY 6 MONTHS
Reid, 2002138 12 monthsNonvertebral fractureIntermediate1/611/590.97 (0.06, 15.65)
Reid, 2002138 12 monthsVertebral fracturesIntermediate0/610/59NC
0.25 MILLIGRAMS, EVERY 3 MONTHS
Reid, 2002138 12 monthsNonvertebral fractureIntermediate0/601/590.13 (0.00, 6.71)
Reid, 2002138 12 monthsVertebral fracturesIntermediate0/600/59NC
0.5 MILLIGRAMS, EVERY 3 MONTHS
Reid, 2002138 12 monthsNonvertebral fractureIntermediate1/581/591.02 (0.06, 16.46)
Reid, 2002138 12 monthsVertebral fracturesIntermediate0/580/59NC
1 MILLIGRAM, EVERY 3 MONTHS
Reid, 2002138 12 monthsNonvertebral fractureIntermediate2/531/592.2 (0.22, 21.7)
Reid, 2002138 12 monthsVertebral fracturesIntermediate0/530/59NC
*

High-risk: 1) transplant population, or 2) study entry criteria require T score ≤-2.5, or 3) study entry criteria require≥1 fracture, or 4) ≥ 50% population has 1 or more fractures at baseline or 5) Significant neuromuscular impairment. Intermediate-risk: 1) study entry criteria require T score ≤1.5, or 2) 10–50% of population has one or more fracture at baseline, or 3) study population has chronic disease that is commonly treated with glucocorticoids or 4) in the absence of data on BMD or fractures, mean age of population > 62 years. Low-risk: 1) study entry criteria require T score ≤0.0, or 2) < 10% of population has BMD =8 g/cm2 at baseline, or 3) 0–10% of population has one or more fracture at baseline, or in the absence of data on BMD or fracture, mean age of population <62 years. Unknown risk: BMD, fracture history and age not reported as entry criteria or in baseline characteristics of population. NC= not calculable.

From: 3, Results

Cover of Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis [Internet].
Comparative Effectiveness Reviews, No. 12.
MacLean C, Alexander A, Carter J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.